» Articles » PMID: 2941420

Physicochemical Properties of Apolipoprotein(a) and Lipoprotein(a-) Derived from the Dissociation of Human Plasma Lipoprotein (a)

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1986 Jul 5
PMID 2941420
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Chemical reduction of human plasma lipoprotein(a) (Lp(a)) yielded two water-soluble products which were separated by rate zonal ultracentrifugation. Apolipoprotein(a) (apo(a)) was completely recovered from the bottom of the gradient, whereas lipoprotein(a-) (Lp(a-)), which contained all of the lipids and apo-B100 of Lp(a), floated. By the techniques of circular dichroism and viscometry Lp(a-) was identical to low density lipoprotein (LDL). Lp(a-) was slightly larger in mass than autologous LDL and contained proportionally more triglyceride. The difference in mass between Lp(a) and Lp(a-) was accounted for by the loss of 2 molecules of apo(a) from the Lp(a) particle. The molecular weight of reduced and carboxymethylated apo(a) was 281,000 as determined by sedimentation equilibrium in 6 M guanidine HCl. By circular dichroism the structure of apo(a) was mostly random (71%) with the remainder representing 8% alpha-helix and 21% beta-sheet; its intrinsic viscosity, 28.3 cm3/g, was consistent with an extended flexible coil. The amino acid composition was characterized by an unusually high content of proline (11.4 mol %) as well as tryptophan, tyrosine, arginine, threonine, and a low amount of lysine, phenylalanine, and isoleucine. Apo(a) contained 28.1% carbohydrate by weight represented by mannose, galactose, galactosamine, glucosamine, and sialic acid in an approximate molar ratio of 3:7:5:4:7, respectively. Overall, the structure of Lp(a) appears to be consistent with a rigid spherical LDL-like core particle which, as a consequence of its association with a flexible glycoprotein such as apo(a), favors the entrapment of significant amounts of hydrodynamically associated solvent. Furthermore, the Lp(a-) remnant generated by the removal of apo(a) from Lp(a) was similar in structure but not identical to autologous LDL.

Citing Articles

Lipoprotein(a) and cardiovascular disease.

Boffa M, Koschinsky M Biochem J. 2024; 481(19):1277-1296.

PMID: 39302109 PMC: 11555715. DOI: 10.1042/BCJ20240037.


Diallyl disulphide inhibits apolipoprotein(a) expression in HepG2 cells through the MEK1-ERK1/2-ELK-1 pathway.

Ma X, Liu Y, Tan Y, Qu K, He X, Zhang H Lipids Health Dis. 2017; 16(1):223.

PMID: 29178936 PMC: 5702159. DOI: 10.1186/s12944-017-0616-1.


Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk.

Yeang C, Clopton P, Tsimikas S J Clin Lipidol. 2016; 10(6):1389-1396.

PMID: 27919356 PMC: 8545497. DOI: 10.1016/j.jacl.2016.09.012.


Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Nordestgaard B, Langsted A J Lipid Res. 2016; 57(11):1953-1975.

PMID: 27677946 PMC: 5087876. DOI: 10.1194/jlr.R071233.


Plasma anti-α-galactoside antibody mediates lipoprotein(a) binding to macrophages.

Sheela B, George G, Mandagini G, Appukuttan P Glycoconj J. 2016; 33(6):953-961.

PMID: 27540729 DOI: 10.1007/s10719-016-9713-z.